Watchlist Price Alert

Delcath Systems Inc. (DCTH)

NASDAQ: DCTH · Real-Time Price · USD

15.99

0.52 (3.36%)

At close: May 15, 2025, 3:59 PM

16.11

0.72%

After-hours: May 15, 2025, 07:14 PM EDT

3.36% (1D)

Bid	15.34
Market Cap	557.05M
Revenue (ttm)	52.21M
Net Income (ttm)	-14.21M
EPS (ttm)	-0.45
PE Ratio (ttm)	-35.54
Forward PE	20.9
Analyst	Strong Buy

Ask	16.65
Volume	494,993
Avg. Volume (20D)	456,200
Open	15.44
Previous Close	15.47
Day's Range	15.34 - 16.10
52-Week Range	6.33 - 16.97
Beta	0.72

About DCTH

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DCTH

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DCTH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Delcath Systems has released their quartely earnings on May 8, 2025:

Revenue of $19.8M exceeds estimates by $2.97M, with 530.77% YoY growth.

EPS of 0.03 misses estimates by 0.00, with 106.67% YoY growth.

Why Price Moved

1 week ago

+23.69%

Delcath Systems shares are trading higher after th... Unlock content with Pro Subscription

2 months ago

-1.56%

Delcath Systems shares are trading lower after the company reported worse-than-expected Q4 EPS results.

News

22 hours ago · businesswire.com

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...

6 days ago · businesswire.com

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

1 week ago · seekingalpha.com

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

Delcath Systems, Inc. (NASDAQ:DCTH ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard...

1 week ago · zacks.com

Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.43 per share a year ago.

1 week ago · businesswire.com

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancer...

2 weeks ago · businesswire.com

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U...

3 weeks ago · businesswire.com

Delcath Systems to Host First Quarter 2025 Earnings Call

1 month ago · zacks.com

Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock?

Delcath Systems (DCTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t...

1 month ago · businesswire.com

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the public...

1 month ago · seekingalpha.com

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Delcath Systemsbeat Q4 sales estimates. This was driven by increased adoption of HEPZATO KIT. However, the stock fell due to the Biotech/Medtech bear market. Delcath reported its first profitable quar...

Load More News